Yahoo Web Search

  1. Yahoo Finance Results

  2. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Index (PMI) data, output in the Healthcare sector is rising.

  3. Pfizer’s PFE strong second-quarter results stole the show this week. Other than that, the European Commission approved Pfizer’s first oncology biosimilar and a second indication for its JAK ...

    69.06+0.21 (+0.31%)

    at Fri, Aug 17, 2018, 15:02PM EST - U.S. Markets closed

    After Hours 69.07 +0.01 (+0.01%)

    Delayed Quote

    • Open 68.78
    • High 69.24
    • Low 68.70
    • Prev. Close 68.85
    • 52 Wk. High 69.24
    • 52 Wk. Low 52.83
    • P/E 142.39
    • Mkt. Cap 183.67B
  4. NASDAQ: ACAD) Agenus Inc (NASDAQ: AGEN) Arsanis Inc (NASDAQ: ASNS) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) Citius Pharmaceuticals Inc (NASDAQ: CTXR) Clementia Pharmaceuticals ...

  5. Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss

    Zacks via Yahoo FinanceAug 03 16:07 PM

    The milestone payment was paid for initiation of a phase I study, evaluating Aduros anti-CD27 antibody in combination with Merck’s Keytruda (pembrolizumab) for treatment of adults with ...

  6. Agenus Inc. AGEN is expected to report second-quarter 2018 results on Aug 2. In the last reported quarter, the company reported a negative earnings surprise of 50%. In the last four quarters ...

  7. With president Trump demanding lower prices and more competition in the industry, it would appear to be a challenging climate ahead for pharmaceutical manufacturers, but the latest quarterly ...

  8. Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2

    Zacks via Yahoo FinanceJul 31 20:00 PM

    Incyte Corporation INCY reported mixed results for the second quarter of 2018, wherein earnings missed estimates, while revenues topped the same. The company reported a net income of 26 cents ...

  9. PFE vs. MRK: Which Stock Should Value Investors Buy Now?

    Zacks via Yahoo FinanceAug 03 13:30 PM

    Pfizer has a Zacks Rank of #2 (Buy), while Merck has a Zacks Rank of #3 (Hold) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions ...

  10. Pfizer (PFE) Beats on Q2 Earnings & Sales, Ups Profit View

    Zacks via Yahoo FinanceJul 31 13:59 PM

    Higher sales of key brands Ibrance, Eliquis and Xeljanz made up for loss of exclusivity for some products, lower sales of legacy Established Products in developed markets and continued supply ...

  11. Merck, Eisai Get FDA Approval for Lenvima Label Expansion

    Zacks via Yahoo FinanceAug 17 14:18 PM

    Merck and Co., Inc. MRK along with its Japanese partner Eisai Co., Ltd. announced that their tyrosine kinase inhibitor, Lenvima (lenvatinib) has received FDA approval ...

  1. Ads
    related to Merck & Co., Inc